{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"24","value":"50.5"}]}],"title":"Cycle 2 (n=338)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4","value":"68.3"}]}],"title":"Cycle 6 (n=240)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"87.5"}]}],"title":"Cycle 8 (n=32)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"338"}],"units":"Participants"}],"description":"Serum samples for measurement of CD19+ lymphocytes were taken pre-dose (within 15 minutes before rituximab infusion). CD19+ lymphocyte counts were measured by flow cytometry using a fluorescent-activated cell sorter (FACS).","groups":[{"description":"Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide, hydroxydaunorubicin \\[doxorubicin\\], Oncovin \\[vincristine\\], prednisone) or CVP (cyclophosphamide, vincristine, prednisone) in combination with rituximab 375 mg/m\\^2 administered by intravenous (IV) infusion on Day 1 of each cycle.","id":"OG000","title":"Rituximab 375 mg/m^2"}],"paramType":"NUMBER","populationDescription":"Per-protocol evaluable population: All patients who received rituximab by faster infusion in Cycle 2 and who did not experience a Grade 3 or 4 infusion-related reaction during the rituximab infusion given at the standard rate during Cycle 1. Only patients with pre-dose CD19+ lymphocyte counts at each time point were included in the analyses.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 2 and either Cycle 6 or 8 (last cycle)","title":"Percentage of Patients Who Had Undetectable Levels of CD19+ Lymphocytes at Cycle 2 and Either Cycle 6 or 8 (Last Cycle)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}